Press releases
Press releases dating back to 2009 are available below. Search them by keyword or browse by year/business category. Press releases for our local operating companies can be viewed on our country websites.
-
EACS 2019: ViiV Healthcare to present 17 abstracts from its portfolio addressing the diverse needs of people living with HIV
Data presentations expand understanding of ViiV Healthcare’s pipeline for heavily treatment-experienced populations, and look deeper into its 2-drug regimen studies
Read more -
GSK delivers sales of £9.4 billion +16% AER, +11% CER (Pro-forma +6% CER*)
GSK delivers sales of £9.4 billion +16% AER, +11% CER (Pro-forma +6% CER*) Total EPS 31.4p +9% AER, -1% CER; Adjusted EPS 38.6p +9% AER, +1% CER
Read more -
Intravenous Benlysta is the first biologic treatment to be approved for children with lupus in Europe
GSK today announced that the European Commission has adopted a decision to extend to children five years and older, the existing adult indication for intravenous Benlysta (belim...
Read more -
GSK candidate vaccine demonstrates sustained level of protection against active pulmonary tuberculosis
Final analysis of phase IIb study published today in the New England Journal of Medicine and presented at the 50th Union World Conference on Lung Health. Final results confi...
Read more -
GSK starts a phase III clinical programme for a potential first-in-class antibiotic, gepotidacin
First in a new chemical class of antibiotic with a mechanism of action distinct from any currently approved antibiotic. Investigating use for uncomplicated urinary tract infect...
Read more -
GSK agrees to divest rabies and tick-borne encephalitis vaccines to Bavarian Nordic
GSK to receive upfront payment of approximately EUR301 million (£259m) and milestone payments for a total consideration of up to EUR955 million (£822m)
Read more -
Global Fund Replenishment - 2019 media statement
“The Global Fund is the world's largest financier of prevention, treatment, and care programmes for three of the deadliest diseases in the world - AIDS, TB, and malaria. Its inv...
Read more -
GSK and Lyell Immunopharma join forces to develop the next generation of cancer cell therapies
Collaboration will combine Lyell’s technologies with GSK’s pipeline of cell therapies and manufacturing capability
Read more -
GSK submits filing to FDA for Trelegy Ellipta use in patients with asthma
GlaxoSmithKline plc (GSK) and Innoviva, Inc. (INVA) today announced the filing of a supplemental New Drug Application (sNDA) to the US Food and Drug Administration (FDA) seeking...
Read more -
IDWeek 2019: ViiV Healthcare to present 20 abstracts from its innovative R&D portfolio with focus on 2-drug and long-acting regimens and mental health impact of HIV
Presentations include six-year data for the investigational regimen of cabotegravir and rilpivirine.
Read more -
Nucala significantly reduces exacerbations in first global prospective real-world study of a biologic in severe eosinophilic asthma
Results from interim analysis of REALITI-A study presented at ERS conference
Read more -
Phase 3 PRIMA trial of Zejula® (niraparib) is the first study to show a PARP inhibitor significantly improves PFS, regardless of biomarker status, when given as monotherapy in women with first-line platinum responsive advanced ovarian cancer
The PRIMA study demonstrates that niraparib treatment resulted in a 38% reduction in the risk of disease progression or death in the overall study population when compared to pl...
Read more -
GSK presents new data showing promising anti-tumour activity with GSK3359609, an ICOS receptor agonist, in combination with pembrolizumab in head and neck squamous cell carcinoma (HNSCC)
Data presented at ESMO 2019 support initiation of phase II/III registrational trial with pembrolizumab in first-line recurrent/metastatic HNSCC.
Read more -
Real-world effectiveness evidence among GSK data presented at ERS 2019
GlaxoSmithKline will for the first time share data on the effectiveness of mepolizumab in severe eosinophilic asthma patients from multiple countries in a real-world setting. In...
Read more -
GSK receives positive CHMP opinion for intravenous Benlysta in children with lupus aged five years and above
GSK today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending the use of intr...
Read more -
Nucala is the first biologic approved in the US for six to 11-year-old children with severe eosinophilic asthma
GlaxoSmithKline (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Nucala (mepolizumab) for use in children as young as six years old wh...
Read more -
GSK to present data from its innovative oncology portfolio at ESMO Congress 2019
GSK today announced that data from its growing oncology pipeline will be presented at the European Society for Medical Oncology Congress in Barcelona, Spain, September 27 - Octo...
Read more -
GSK announces positive headline results from the pivotal DREAMM-2 study for multiple myeloma
Belantamab mafodotin (GSK2857916) on track for regulatory submission by the end of 2019
Read more -
ViiV Healthcare reports positive phase III study results of investigational, long-acting, injectable HIV-treatment regimen administered every two months
ATLAS-2M study met its primary endpoint, showing similar efficacy of cabotegravir and rilpivirine administered every eight weeks compared to four-week administration.
Read more -
GSK submits first regulatory application for daprodustat in Japan for patients with renal anaemia due to chronic kidney disease
GlaxoSmithKline plc (LSE/NYSE: GSK) today announced the submission of a Japanese New Drug Application (JNDA) to the Ministry of Health, Labour and Welfare seeking marketing appr...
Read more
Find out more about us
-
About us
We are a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer.
-
Products
We research and develop a broad range of innovative products in three primary areas of Pharmaceuticals, Vaccines and Consumer Healthcare
-
Research and development
Science can improve health and well-being in so many ways, from the development of everyday convenience healthcare products through to life-saving medicines and vaccines.
-
Behind the science
Explore innovations in medicines, vaccines and consumer healthcare from inside and outside our labs.
